Endometriosis diagnosis just got turned on its head
The process of receiving an endometriosis diagnosis is often long, frustrating and painful. New guidelines hope to change that.
Good news for the one in nine girls, women and people assigned female at birth who are affected by endometriosis – diagnosis just got significantly less painful and invasive.
You're unlikely to hear any story of someone getting an endometriosis diagnosis that's uncomplicated and straightforward.
It often takes years to be diagnosed, as misdiagnosis is common, waitlists are long, and painful, invasive surgeries are often required to officially diagnose the disease.
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (Ranzcog), have now recommended less invasive and far less painful avenues for diagnosis.
Diagnosing endometriosis through ultrasound
Ranzcog now recommends that patients be offered an ultrasound or MRI instead of laparoscopic surgery.
The living evidence guideline for endometriosis replaces the guidelines that have been in place since 2021, and will be updated in line with emerging research and evidence. The Australian Coalition for Endometriosis chair, Jess Taylor, said this is 'critical' due to the amount of new research looking into the disease.
From November, a new Medicare item number for an endometriosis ultrasound will look for endometriosis tissue beyond the uterus, fallopian tubes and ovaries, including the ligament holding the uterus inside the pelvis and other areas external to the uterus.
From November, a new Medicare item number for an endometriosis ultrasound will look for endometriosis tissue beyond the uterus, fallopian tubes and ovaries, including the ligament holding the uterus inside the pelvis and other areas external to the uterus.
Dr Marilla Druitt worked on the development of the guidelines and said, 'that Medicare item number will hopefully drive more thorough looking and more thorough assessment.'
By beginning the diagnosis process with an ultrasound, patients won't have to wait on extensive waitlists for surgery, so they will hopefully be able to access treatment earlier.
The updated guidelines also recommend hormonal treatment as the first-line therapy, but physiotherapy and accessing psychological care are now encouraged to help treat pelvic pain and endometriosis too. Image: iStock
Though more sonographers need to gain accreditation to improve access.
Physiotherapy and psychological care for endometriosis
The updated guidelines also recommend hormonal treatment as the first-line therapy, but physiotherapy and psychological care are now encouraged to help treat pelvic pain and endometriosis too.
Ranzcog suggests that if patients experience no improvement in symptoms after three months of treatment, GPs should turn to alternative medications.
Experts hope the new guidelines will ensure there isn't a delay in patients being able to access treatment for the painful and often debilitating symptoms of endometriosis. Image: Pexels
Endometriosis cancer risk
If patients have concerns about their cancer risk, the new guidelines suggest they should be told 'that although they may have a small increase in ovarian and endometrial cancer, the increase in absolute risk compared with women in the general population is low; and that they may have a reduced risk of cervical cancer'.
Experts hope the new guidelines will ensure there isn't a delay in patients being able to access treatment for the painful and often debilitating symptoms of endometriosis.
Originally published as Endometriosis diagnosis just got turned on its head
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
7 days ago
- Sky News AU
Medical specialist consultations drop by ten per cent as costs rise
Medicare data shows the number of Australians visiting medical specialists has fallen ten per cent since 2019. This is partly due to the costs for initial appointments being upwards of $900. In response, the government has committed to putting thousands of specialist doctors' fees online so Australians can shop around.
Sky News AU
04-06-2025
- Sky News AU
‘Bring your credit card': Labor's Medicare election promises lashed
Sky News host Paul Murray discusses Prime Minister Anthony Albanese's Medicare election promise. 'Now, we know the prime minister was distracting Australia and successfully so by telling lies during the election,' Mr Murray said. 'This is all you'll need to see a doctor, despite the fact 85 per cent of doctors said no you will still need to bring your credit card.'
News.com.au
04-06-2025
- News.com.au
Health Check: Whether stoic or simply too poor, Australians spurn GP visits
Doctor visits dipped in April, reversing a recovery trend Mayne Pharma threatens to go legal in takeover dispute … but peace erupts at Cann Group with settlement of legal spat We're either a healthy lot, rely on Dr Google or simply can't afford to visit a GP anymore. Take your pick as to why our doctor visitations are running below the historic trend. Medicare data for April shows a resumption of a decline in doctors' visits, thus reversing a recent recovery. Bell Potter says the 12-month rolling rate slipped back to 0.8% from 2.3% in March and now is below the long-term median 1.4% growth. In April last year, the rolling rate had dipped to -3%. The slippage was most apparent in Queensland, which shows what stoic souls they are up north. Or maybe they couldn't get to their clinics because they were hemmed in by floods. The rate of doctors' visits has a direct impact on diagnostic imaging volumes and thus is relevant for stocks such as Sonic Healthcare (ASX:SHL), Integral Diagnostics (ASX:IDX), Healius (ASX:HLS) and Australian Clinical Labs (ASX:ACL). (Healius sold its 69 medical centres to private equity firm BGH Capital for $500 million in November 2020.) Macquarie Equities says both pathology and imaging volumes grew 4% in April, year on year. But the DI providers look to be protected by more expensive procedures – 'higher fee modalities', as the firm puts it – with benefits paid rising 8% in April for pathology and 7% for imaging. On the bright side, face-to-face GP visits have held up relative to telehealth and the former is likely to result in diagnostic referrals. So it's a bit of a mixed picture. The re-elected Albo's pledge to extend bulk billing might also ramp up volumes. What will restrain the pain at Mayne? Mayne Pharma's (ASX:MYX) takeover is in the balance, with a 10-day consultation period expiring without suitor Cosette Pharmaceuticals pulling the plug. Cosette alleged that events had resulted in a 'material adverse change', thus triggering the consultation period. Mayne denies these events were material. The FDA has accused Mayne Pharma of downplaying the risks of its oral birth control pill, Nextstellis. Mayne Pharma now says the agency is satisfied the company has addressed the identified issues. Mayne is also in a tat-for-tat legal dispute with the Nasdaq-listed Therapeutics MD, relating to Mayne's purchase of assets from the latter in 2022. While Cosette is yet to walk, the terms of the scheme implementation deed (SID) enable the suitor to do so any time up to the second court hearing to approve the deal. The affair may end up in the courts in a different way, given Mayne 'intends to take all reasonable steps to enforce its rights under the SID.' This includes litigation, of course. Mayne shares this morning surged 5%, but they remain 32% below Cosette's $7.40 a share cash offer. So investors are saying the deal might have a pulse, but not at the original offer price. Cann Group pots legal settlement Medical cannabis play Cann Group (ASX:CAN) has settled a legal dispute with the NZ-listed Rua Biosciences, which had sued a Cann subsidiary over a manufacturing and supply agreement. As is the norm, the agreement is confidential but doesn't involve any money changing hands. Instead, the parties have agreed that Cann will supply 'certain medicinal cannabis products' to Rua under 'agreed market standard commercial terms.' As far as legal spats go, it sounds like a reasonable result. Across the Tasman, Rua shares were up more than 7% this morning Cann shares were about 3% off the pace, having lost 65% of their value year to date. The first Australian company to receive an Australian cannabis research and cultivation licence, Cann produces from its modern Mildura facility. But in the current oversupplied market, it's not easy being green. Radiopharm tackles HER-2 cancers Radiopharm Theranostics (ASX:RAD) has dosed the first patient in its phase I trial to treat advanced HER2-positive solid tumours. A human epidermal growth factor receptor, HER2 is expressed in a variety of tumours including some breast cancers. Dubbed Heat, the study road tests Radiopharm's lutetium isotope-based therapy. Taking place at multiple local centres, the study has the usual safety and tolerability remits. It also aims for the optimal dosage for a phase II trial, as well as early efficacy signals. 'Despite progressive improvements in the management of metastatic HER2-positive disease, the majority of patients experience disease progression on current standard of care and require further therapeutic options,' Radiopharm CEO Riccardo Canevari says. On Monday, the company said preclinical data from another program showed 'favorable biodistribution and ... maintained tumor uptake.' This one refers to its lutetium-based monoclonal antibody RV01, which targets solid tumours expressing the B7H3 protein. This one is via a joint venture with Houston's MD Anderson Cancer Center to develop at least four radiopharmaceutical products. The next step is FDA assent to run a first-in-human trial, which the company hopes to kick off in 2026.
